FIGURE 5.
Data of the comparative analysis for the safety outcomes of hyperkalaemia and angioedema. Hyperkalaemia was defined as serum potassium >5.5 mmol/L. Sac/Val, sacubitril‐valsartan.
Data of the comparative analysis for the safety outcomes of hyperkalaemia and angioedema. Hyperkalaemia was defined as serum potassium >5.5 mmol/L. Sac/Val, sacubitril‐valsartan.